217 reports of this reaction
1.9% of all TAMOXIFEN CITRATE reports
#9 most reported adverse reaction
BREAST CANCER is the #9 most commonly reported adverse reaction for TAMOXIFEN CITRATE, manufactured by Mayne Pharma. There are 217 FDA adverse event reports linking TAMOXIFEN CITRATE to BREAST CANCER. This represents approximately 1.9% of all 11,158 adverse event reports for this drug.
Patients taking TAMOXIFEN CITRATE who experience breast cancer should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER is a less commonly reported adverse event for TAMOXIFEN CITRATE, but still significant enough to appear in the safety profile.
In addition to breast cancer, the following adverse reactions have been reported for TAMOXIFEN CITRATE:
The following drugs have also been linked to breast cancer in FDA adverse event reports:
BREAST CANCER has been reported as an adverse event in 217 FDA reports for TAMOXIFEN CITRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER accounts for approximately 1.9% of all adverse event reports for TAMOXIFEN CITRATE, making it a notable side effect.
If you experience breast cancer while taking TAMOXIFEN CITRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.